SCYX SCYNEXIS Inc.

2.31
-0.06  -3%
Previous Close 2.37
Open 2.35
Price To book 1.96
Market Cap 61729005
Shares 26,722,513
Volume 275,631
Short Ratio 5.52
Av. Daily Volume 274,451

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Clinical hold placed on the initiation of intravenous (IV) SCY-078 until the FDA completes a review of all data. Clinical hold follows three mild-to-moderate thrombotic events in healthy volunteers - announced March 2, 2017. Noted May 8, 2017 that Phase 2 trial to be initiated in 2018.
Intravenous SCY-078
Phase 2 initation of dosing annunced August 3, 2017 - data due mid-2018.
SCY-078 - oral
Vulvovaginal candidiasis (VVC)
Phase 3 open label trial commenced 2Q 2017.
SCY-078 - oral (FURI)
Invasive candidiasis